
Kadmon Holdings, Inc. KDMN
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
169 M |
Market Cap[1] |
$ 1.7 B |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Revolution Medicines
RVMD
|
$ 159.7 | -1.84 % | $ 30.4 B | Nasdaq Global Select Market | ||
|
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | Nasdaq Global Market | ||
|
Legend Biotech Corporation
LEGN
|
$ 16.25 | 0.87 % | $ 5.99 B | Nasdaq Global Select Market | ||
|
CytomX Therapeutics
CTMX
|
$ 1.91 | -1.55 % | $ 263 M | Nasdaq Global Select Market | ||
|
Krystal Biotech
KRYS
|
$ 314.77 | 5.43 % | $ 9.11 B | Nasdaq Global Market,SPB | ||
|
Kura Oncology
KURA
|
$ 7.34 | -2.07 % | $ 644 M | Nasdaq Global Select Market | ||
|
Inhibikase Therapeutics
IKT
|
$ 1.39 | 0.36 % | $ 137 M | Nasdaq Capital Market | ||
|
Phathom Pharmaceuticals
PHAT
|
$ 5.31 | -3.45 % | $ 387 M | Nasdaq Global Select Market,SPB | ||
|
Heron Therapeutics
HRTX
|
$ 0.27 | -3.26 % | $ 45 M | Nasdaq Global Select Market,SPB | ||
|
Inovio Pharmaceuticals
INO
|
$ 1.69 | 3.37 % | $ 79.2 M | Nasdaq Global Select Market | ||
|
Corvus Pharmaceuticals
CRVS
|
$ 10.19 | 0.22 % | $ 805 M | Nasdaq Global Market | ||
|
SIGA Technologies
SIGA
|
$ 2.81 | 2.75 % | $ 201 M | Nasdaq Global Select Market | ||
|
Aytu BioScience
AYTU
|
$ 2.66 | -0.19 % | $ 32.8 M | Nasdaq Capital Market | ||
|
Heat Biologics, Inc.
HTBX
|
- | -5.76 % | $ 99.8 M | Nasdaq Capital Market | ||
|
Innoviva
INVA
|
$ 18.36 | 0.3 % | $ 1.24 B | Nasdaq Global Select Market | ||
|
BioCardia
BCDA
|
$ 0.77 | -2.06 % | $ 5.13 M | Nasdaq Global Select Market | ||
|
Kindred Biosciences, Inc.
KIN
|
- | 0.11 % | $ 419 M | Nasdaq Global Select Market | ||
|
Syndax Pharmaceuticals
SNDX
|
$ 8.55 | -7.07 % | $ 741 M | Nasdaq Global Select Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 1.72 | -7.77 % | $ 11 B | Nasdaq Capital Market | ||
|
Shineco, Inc.
TYHT
|
- | -3.90 % | $ 97.2 M | Nasdaq Global Select Market | ||
|
ORIC Pharmaceuticals
ORIC
|
$ 7.66 | -4.25 % | $ 673 M | Nasdaq Global Select Market | ||
|
Millendo Therapeutics, Inc.
MLND
|
- | -5.36 % | $ 20.2 M | Nasdaq Global Select Market | ||
|
Oramed Pharmaceuticals
ORMP
|
$ 3.9 | 0.78 % | $ 161 M | Nasdaq Global Select Market | ||
|
Certara
CERT
|
$ 11.25 | 1.72 % | $ 1.8 B | Nasdaq Global Select Market | ||
|
PainReform Ltd.
PRFX
|
$ 0.63 | -4.8 % | $ 408 K | Nasdaq Capital Market | ||
|
Intec Pharma Ltd
NTEC
|
- | -12.45 % | $ 17.7 M | Nasdaq Capital Market | ||
|
Anika Therapeutics
ANIK
|
$ 13.74 | 6.89 % | $ 197 M | Nasdaq Global Select Market,SPB | ||
|
Prothena Corporation plc
PRTA
|
$ 8.38 | 1.39 % | $ 451 M | Nasdaq Global Select Market,SPB | ||
|
Aprea Therapeutics
APRE
|
$ 0.46 | 2.6 % | $ 3.01 M | Nasdaq Global Select Market,SPB | ||
|
Galectin Therapeutics
GALT
|
$ 3.0 | 2.92 % | $ 192 M | Nasdaq Global Select Market | ||
|
Processa Pharmaceuticals
PCSA
|
$ 1.7 | -2.3 % | $ 2.23 M | Nasdaq Global Select Market | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 67.94 | -3.04 % | $ 7.06 B | Nasdaq Capital Market,SPB | ||
|
Progenity, Inc.
PROG
|
- | -3.47 % | $ 164 M | Nasdaq Global Select Market | ||
|
China SXT Pharmaceuticals
SXTC
|
$ 2.84 | -0.7 % | $ 1.93 M | Nasdaq Global Select Market | ||
|
Genprex
GNPX
|
$ 1.73 | 3.56 % | $ 1.61 M | Nasdaq Capital Market | ||
|
Strongbridge Biopharma plc
SBBP
|
- | 1.52 % | $ 136 M | Nasdaq Global Select Market | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
$ 21.27 | -1.71 % | $ 33.6 B | NYSE | ||
|
Protara Therapeutics
TARA
|
$ 2.33 | 0.22 % | $ 99.8 M | Nasdaq Global Market | ||
|
Innate Pharma S.A.
IPHA
|
$ 1.0 | -24.81 % | $ 89.6 M | Nasdaq Global Select Market | ||
|
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M | Nasdaq Capital Market | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 61.57 | 5.22 % | $ 11.8 B | Nasdaq Global Select Market,SPB | ||
|
Bio-Techne Corporation
TECH
|
$ 72.74 | 0.15 % | $ 11.3 B | Nasdaq Global Select Market,SPB | ||
|
Matinas BioPharma Holdings
MTNB
|
$ 0.91 | 6.35 % | $ 4.98 M | NYSE American | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 8.21 | -5.52 % | $ 175 K | Nasdaq Global Select Market,SPB | ||
|
Milestone Pharmaceuticals
MIST
|
$ 0.46 | 10.45 % | $ 48.9 M | Nasdaq Global Select Market | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
$ 42.18 | -1.04 % | $ 48.3 B | NYSE | ||
|
Scholar Rock Holding Corporation
SRRK
|
$ 47.99 | 6.46 % | $ 5.5 B | Nasdaq Global Select Market | ||
|
Lipocine
LPCN
|
$ 1.54 | -3.75 % | $ 8.39 M | Nasdaq Global Select Market | ||
|
Seres Therapeutics
MCRB
|
$ 1.45 | 2.48 % | $ 12.8 M | Nasdaq Global Select Market | ||
|
Madrigal Pharmaceuticals
MDGL
|
$ 398.15 | -5.65 % | $ 8.93 B | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.